Tasigna 'Discontinued'

Premium

Novartis is stopping the development of its drug Tasigna — which was being developed as an initial therapy for patients with gastrointestinal stromal tumors — because it's unlikely that the drug will help patients live longer than those on the current standard of care, Gleevec, report The Wall Street Journal's Anita Greil. An independent data-monitoring committee recommended the discontinuation after comparing Tasigna and Gleevec in a late-stage study, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.